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Abstract
Optimal methods of stem cell mobilization in multiple myeloma are undefined, and 
contaminating clonotypic cells could contribute to disease recurrence.  A phase 2 trial of 
intravenous melphalan (60mg/m
2) and G-CSF (10ug/kg/d) for mobilization was performed.  To 
enhance reliability, contamination was assessed with two sensitive methods, immunoglobulin 
light- and heavy-chain variable region patient-specific limiting-dilution PCR. We evaluated 29 
stem cell components (SCC) from fifteen patients; for 9 SCC, only VL PCR was used because of 
light chain disease or technical problems with VH primers.  For 20 SCC, VL and VH PCR results 
were highly correlated (r
2 = 0.93, p << 0.01) with 35% (7/20) having identical estimates. VH PCR 
gave significantly higher estimates for 8, and VL PCR for 5, SCC, supporting the utility of 
employing two methods. Estimated clonotypic contamination per SCC was 0.0009% (0-0.1) or 
0.5 x 10
4 clonotypic cells per kg (0-41.2), and contamination correlated with CD34+ cells 
collected (r
2 = 0.42, p << 0.01).  Melphalan-mobilized SCC contain minimal clonotypic 
contamination.  
Corresponding author’s e-mail: comenzor@mskcc.org
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Introduction
Multiple myeloma (MM) is an incurable hematologic malignancy.  Autologous stem cell 
transplantation (SCT) prolongs survival compared to conventional chemotherapy (1-3) though 
patients invariably relapse (3).  Autologous SCT followed by reduced intensity allogeneic SCT 
may improve response rates and survival (4) but, even for such tandem SCT regimens, the 
contribution to disease relapse of autologous stem cell components (SCC) contaminated by 
malignant plasma cells will need to be evaluated (5-9).  
The optimal mobilization strategy in myeloma might combine anti-myeloma effect with 
collection of adequate, minimally contaminated stem cell components. Over the past two years 
we conducted a phase 2 trial employing intravenous melphalan (60mg/m
2) and G-CSF 
(10ug/kg/d) for stem cell mobilization and reduction of disease.  We assessed clonotypic 
contamination in SCC by limiting-dilution polymerase chain reaction (PCR) assays employing 
immunoglobulin (Ig) light- and heavy-chain (VL and VH) patient-specific primer sets 
(CDR1/CDR3) (5, 10-13), a strategy that combines a sensitive method and an independent check 
on estimates of contamination. In this report we describe the technical aspects of the assessment 
of tumor cell contamination of SCC from patients with myeloma mobilized with melphalan.
Methods
Patients with chemoresponsive multiple myeloma (> 50% reduction in M protein) were 
enrolled on this IRB approved protocol after providing written informed consent (14).  Bone 
marrow and stem cell specimens were obtained for molecular studies, and data were recorded, as 
previously described (15).  Stem cell collections began when peripheral blood leukocyte counts 
exceeded 5000/uL.  
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Clonal Ig V genes:  Clonal Ig VL and VH genes were identified as previously described, 
using PCR primers for consensus VH and C￿ or C￿ regions and for V￿ and V￿ subgroups (10-13, 
16, 17).  Sequences of the VDJ (VH) or VJ (VL) regions were evaluated.  VL and VH CDR1/CDR3 
primers were designed and optimized (12, 17-20).  Each primer pair was tested for specificity 
and sensitivity using buffy-coat DNA from normal donors and DNA from the patient’s marrow 
specimen.
Limiting-dilution PCR:  Representative samples were obtained from each SCC without 
manipulation. To estimate the percent of clonotypic cells, limiting-dilution PCR with patient-
specific CDR1/CDR3 primers was performed (10-13, 17-20) with DNA from 2 x 10
5 cells per 
SCC serially log-diluted with buffy-coat DNA. Specimens giving all negative results were 
assessed by RT-PCR, whereas specimens giving positive results underwent further PCR assays, 
in which five to ten identical PCR reactions were performed simultaneously with DNA at each 
dilution.  The linearity of this approach has been validated (13, 18), and the intra-assay 
variability was assessed using a control patient specimen with 1% clonotypic cells, repeating the 
PCR assays for 7 consecutive days.  Each 25 ul PCR reaction contained cellular DNA (diluted as 
above), PCR buffer, 1.5 mM MgCl2, 0.2 mM of each dNTP, 0.4 uM of each primer and 0.5 U of 
Taq (Invitrogen, Carlsbad, CA). Negative controls with and without buffy-coat DNA were 
amplified with each assay. PCR conditions were as previously described; annealing temperatures 
ranged from 50
o to 64
o C, depending on primer pair (16, 20). 
The percent of clonotypic cells per SCC was calculated using a Poisson analysis and 
MAXLIKE software (gift of F. Cremer and M. Moos) as previously described (13).  The amount 
of contamination was estimated by multiplying the percent clonotypic cells (using the higher of 
the VH or the VL estimate) by the total number of cells collected per kg.  
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Statistics: All analyses were performed with PRISM (GraphPad, San Diego, CA) and 
were two-tailed, unless otherwise noted, using a p < 0.05 significance level.
Results and Discussion
Optimal methods for stem cell mobilization in myeloma and for assessment of stem cell 
components (SCC) for contamination have not been defined. We evaluated 29 SCC mobilized 
with melphalan from fifteen patients, twelve with an IgG or IgA paraprotein and three with light 
chain disease (Table 1).  In all cases the clonal Ig VL and VH genes were identified; they were 
distributed among heavy chain subgroups VH2 = 1, VH3 = 8, and VH4 = 3, and light chain 
subgroups V￿1 = 7, V￿4 = 1, V￿1 = 1, V￿2 = 3, and V￿3 = 3.  All genes showed evidence of somatic 
hypermutation  (21, 22).  
Twenty-five of 27 primer sets passed specificity and sensitivity testing (15 VL and 10 VH).  
Two VH primer sets continued to amplify bands similar in size to the target amplicon, despite 
using buffy-coat DNA from three normal donors as substrate and repeated re-design of primers.  
(Most target amplicons were ￿220bp, ranging from 159 to 255bp).  Thus, 10 VH primer sets 
passed testing for the 12 patients with IgG or IgA paraproteins.  Sensitivity testing showed that 
all 25 specific primer sets had sensitivities < 0.01%.  The coefficient of variation (CV) for 
replicate patient-specific limiting-dilution PCR assays was 24%, acceptable and similar to CVs 
obtained for radioimmunoassays (23, 24).
Results are available for all 29 SCC. Thirty-five percent of the SCC (7/20) successfully 
analyzed by both VL and VH PCR (n=20) had identical estimates by both methods; in five of the 
concordant cases the estimate was zero or none detected (although RT-PCR assays for these 
were positive by both methods).  VL and VH estimates differed for 65% (13/20) of the SCC; in 
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these instances, the higher value was employed as the estimate of contamination. VH PCR was 
significantly higher for 8 (2.9 versus 0.4 x 10
4 cells per kg, p = 0.02 by one-tailed paired t-test), 
whereas VL PCR was higher for 5 SCC (9.2 versus 7.5 x 10
4 cells per kg, p = 0.05).  Results for 
these 20 SCC were highly correlated (Figure 1A; r
2 = 0.93, p << 0.01). For the remaining 9 SCC, 
only VL PCR was used because of light chain disease (n=5) or technical problems with VH primer 
sets (n=4).  
For the 29 SCC examined, estimated clonotypic contamination was 0.0009% (0-0.1) or 
0.5 x 10
4 cells per kg (0-41.2).  Some variability could be explained by the correlation between 
CD34+ cell mobilization and contamination (Figure 1B). There was no correlation between 
contamination and stage of disease (data not shown) or timing of mobilization (Figure 1C).  In a 
study of SCC contamination that involved a similar cohort of patients mobilized with 
cyclophosphamide or ifosfamide-containing regimens and G-CSF, a constant ratio of 
contaminating clonotypic cells to CD34+ cells collected was also observed using a similar PCR 
method (18).  The investigators reported no difference in CD34+ cells obtained on the first or 
second days of collection (18), whereas with melphalan mobilization significantly more CD34+ 
cells were obtained on the second day of collection (Table 1).  
In that study the investigators reported a median of 0.0066% contaminating cells per SCC 
(range, 0-0.71) (18). We performed limiting dilution PCR on 4 SCC mobilized with 
cyclophosphamide and G-CSF from three chemoresponsive myeloma patients and found a 
median of 0.038% contaminating cells per SCC (range, 0.029-0.046), using the same technique 
that demonstrated a median of 0.0009% contamination of melphalan-mobilized SCC.These data 
suggest that melphalan-mobilized SCC contain minimal clonotypic contamination and that the 
assessment of contamination is enhanced by use of Ig VL and VH patient-specific PCR.  
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In a phase 3 trial of SCT for myeloma, cyclophosphamide-mobilized SCC purged by 
CD34-selection were not superior to unpurged components (8).  However, gene-marking studies 
have demonstrated that infused tumor cells in SCC can contribute to relapse (25).   Myeloma 
patients mobilized with melphalan on this trial had minimally contaminated SCC collected, and 
40% of them experienced a further 50% disease reduction (14).  All fifteen patients we report 
had adequate SCC collected, underwent autologous stem cell transplantation with a median of 
6.8 million melphalan-mobilized CD34+ cells per kg (range, 3.1-10.7), and had routine and full 
hematologic recoveries (see Table 1). We believe these results support the further assessment of 
melphalan for stem cell mobilization given its anti-myeloma effect. Such studies can determine 
whether this mobilization strategy has a clinical impact on progression-free and overall survival.
For personal use only. on November 3, 2014.  by guest    www.bloodjournal.org From 8
Acknowledgements
We are grateful for the assistance of Suzanne Costello, Lilian Reich, Nancy Collins, 
Shanta Sharma, Lisa Drake, Joanne Santorsa and the staffs of the Memorial Hospital Donor 
Room and Cytotherapy Laboratory.  Dr. Carmen Martinez current affiliation is Hematology 
Department, Hospital Clinic, Barcelona, Spain.
For personal use only. on November 3, 2014.  by guest    www.bloodjournal.org From 9
References
1. The Myeloma Trialists' Collaborative Group. Combination Chemotherapy Versus 
Melphalan Plus Prednisone as Treatment for Multiple Myeloma: Overview of 6,633 Patients 
From 27 Randomized Trails. J Clin Oncol 1998; 16:3832-3842. 
2.  Bergsagel DE. Chemotherapy of myeloma. In: Malpas JS, Bergsagel DE, Kyle RA, 
Anderson KC, eds. Myeloma Biology and Management, 2
nd edition. New York: Oxford 
University Press; 1998;269-302.
3. Attal M, Harousseau JL, Stoppa AM, et al. Autologous bone marrow transplantation 
versus conventional chemotherapy in multiple myeloma: a prospective randomized trial. N Engl 
J Med 1996;335:91-97.
4. Kröger N, Schwerdtfeger R, Kiehl M, et al.   Autologous stem cell transplantation 
followed by a dose-reduced allograft induces high complete remission rate in multiple myeloma. 
Blood 2002;100:755-760.
5. Corradini P, Voena C, Astolfi M, et al: High-dose sequential chemoradiotherapy in 
multiple myeloma: Residual tumor cells are detectable in bone marrow and peripheral blood cell 
harvests and after autografting. Blood 1995;85:1596-1602.
6. Lemoli R, Fortuna A, Motta MR, et al. Concomitant mobilization of plasma cells and 
hematopoietic progenitors into peripheral blood of multiple myeloma patients: Positive selection 
and transplantation of enriched CD34 cells to remove circulating tumor cells.
Blood 1996;87:1625-34.
7.  Gertz MA, Witzig TE, Pineda AA, Greipp PR, Kyle RA, Litzow MR. Monoclonal 
plasma cells in the blood stem cell harvest from patients with multiple myeloma are associated 
For personal use only. on November 3, 2014.  by guest    www.bloodjournal.org From 10
with shortened relapse-free survival after transplantation. Bone Marrow Transplantation 
1997;19:337–342.
8.  Vescio R, Schiller G, Stewart AK, et al. Multicenter phase III trial to evaluate CD34(+) 
selected versus unselected autologous peripheral blood progenitor cell transplantation in multiple 
myeloma. Blood 1999;93:1858-68.  
9.  Boccadoro M, Omede´ P, Dominietto A, et al. Multiple myeloma: the number of 
reinfused plasma cells does not influence outcome of patients treated with intensified 
chemotherapy and PBPC support. Bone Marrow Transplantation 2000;25:25–9.
10.  Martinelli G, Terragna C, Lemoli RM, et al. Clinical and molecular follow-up by 
amplification of the CDR-III IgH region in multiple myeloma patients after autologous 
transplantation of hematopoietic CD34 stem cells. Haematologica 1999;84:397-404.
11.  Comenzo RL, Wally J, Kica G, et al. Clonal immunoglobulin light chain variable region 
germline gene use in AL amyloidosis: association with dominant amyloid - related organ 
involvement and survival after stem cell transplantation.  Br J Haematology 1999;106:744-51.
12.  Willems P, Verhagen O, Segeren C, et al. Consensus strategy to quantitate malignant 
cells in myeloma patients is validated in a multicenter study.  Blood 2000; 96:63-70. 
13.  Cremer FW, Kiel K, Wallmeier M, Goldschmidt H, Moos M. A quantitative PCR assay 
for the detection of low amounts of malignant cells in multiple myeloma. Ann Oncol, 
1997;8:633-6.
14.  Comenzo RL, Costello S, Reich L, et al.  Results of Autologous Stem Cell 
Transplantation (SCT) Following Stem Cell Mobilization with Melphalan in Myeloma Patients 
[abstract].  Blood 2002;100:435a.
For personal use only. on November 3, 2014.  by guest    www.bloodjournal.org From 11
15.  Moskowitz CH, Stiff P, Gordon MS, et al. Recombinant methionyl human stem cell 
factor and filgrastim for peripheral blood progenitor cell mobilization and transplantation in non-
Hodgkin's lymphoma patients -- results of a phase I/II trial. Blood 1997;89:3136-47.
16.  Comenzo RL, Zhang Y, Martinez C, Osman K, Herrera G. The tropism of organ 
involvement in primary systemic amyloidosis: contributions of Ig VL germline gene use and 
plasma cell burden. Blood 2001;98:714-20.
17.  Cremer FW, Kiel K, Wallmeier M, Haas R, Goldschmidt H, Moos M. Leukapheresis 
products in multiple myeloma: lower tumor load after mobilization with cyclophosphamide plus 
granulocyte colony-stimulating factor (G-CSF) compared with G-CSF alone. Exp Hematol, 
1998;26:969-75.
18.  Kiel K, Cremer FW, Ehrbrecht E, et al. First and second apheresis in patients with 
multiple myeloma: no differences in tumor load and hematopoietic stem cell yield. Bone Marrow 
Transplantation 1998;21:1109–1115.
19. Cremer FW, Ehrbrecht E, Kiel K, et al. Evaluation of the kinetics of the bone marrow 
tumor load in the course of sequential high-dose therapy assessed by quantitative PCR as a 
predictive parameter in patients with multiple myeloma.  Bone Marrow Transplant 2000;26:851-
8.
20.        Comenzo, RL, Michelle D, LeBlanc M, et al.  Mobilized CD34+cells selected as 
autografts in patients with primary light-chain amyloidosis: rationale and application.  
Transfusion 1998;38:60-9 
21.  Sahota S, Leo R, Hamblin T, Stevenson FK. Myeloma VL and VH gene sequences reveal a 
complementary imprint of antigen selection in tumor cells. Blood 1997;89:219-26.
For personal use only. on November 3, 2014.  by guest    www.bloodjournal.org From 12
22. Kosmas C, Viniou N-A, Stamatopoulos K, et al. Analysis of the light chain variable 
region in multiple myeloma. Br J Haematol 1996;94:306-17.
23.  Sendak R, Wang F, Geagan L, et al.  Comparison of Two In Vitro Methods for the 
Measurement of Recombinant Human TSH Bioactivity. Biologicals 2002;30:245-8. 
24.  Nauck MS, Nauck MA, Nauck MA, Marz W, Wieland H. Six methods for the 
determination of C-peptide evaluated.  Clin Chem Lab Med 1999;37:745-51.  
25.  Brenner M, Krance R, Heslop HE, et al. Assessment of the efficacy of purging by using 
gene marked autologous marrow transplantation for children with AML in first complete 
remission. Hum Gene Ther. 1994;5:481-99.
For personal use only. on November 3, 2014.  by guest    www.bloodjournal.org From 13
Table 1.  Data on 15 patients mobilized with melphalan (60mg/m
2) and G-CSF
*All 15 patients had stem cell collections on Day 1. Thirteen had collections on Day 2, and one 
had a 3
rd collection on Day 3, giving a total of 29 collections.  CD34 and clonotypic 
Age  58 (33-73)
Gender 8 men, 7 women
Myeloma protein
                 IgG ￿ = 3, ￿ = 3
                 IgA ￿ = 3, ￿ = 3
                 Light chain only ￿ = 1, ￿ = 1, Non-secretory [￿] = 1
Stage of disease
           II 7
                 III 7
                 Plasma cell leukemia 1
Days from melphalan to first collection 19 (13-22)
Number of leukaphereses  2 (1-5)
Total CD34+ cells collected x 10
6 per kg  14.1 (3.5-40.0)
CD34+ cells x 10
6 per kg infused for SCT 6.8 (3.1-10.7)
Days from SCT to ANC > 500  9 (8-11)
Days from SCT to platelets > 20,000/uL untransfused 12 (10-16)
CD34+ cells in 13 paired (day 1, day 2) collections
                 Day 1               % 1.6   +/- 1.4
                        # (x 10
6 per kg) 3.2   +/- 2.9
                 Day 2                % 1.9   +/- 1.3
                                           # (x 10
6 per kg) 6.8   +/- 5.6
                 Day 1 vs Day 2  (paired t-test)
                       % p = 0.11
                                           # p < 0.01  
Clonotypic cells* in 13 paired (day 1, day 2) collections
                 Day 1                 % 0.009 +/- 0.013
                                            # (x 10
4 per kg) 1.9 +/- 2.7
                 Day 2                  % 0.016 +/- 0.033
                                             # (x 10
4 per kg)   4.0 +/- 7.7
                 Day 1 vs Day 2 (paired t-test)
   % p = 0.44
                                             # p = 0.37
Clonotypic cells* (n = 29 collections) (median (range))
                                            % 0.0009 (0-0.1)
                                            #  (x 10
4 per kg)    0.5 (0-41.2)
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contamination data for the 13 paired collections (means +/- SD), and clonotypic data for all 29 
collections, are shown. To compute estimates of contamination, the higher percentage obtained 
with VL or VH PCR was used.  
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Figure 1. Estimates of clonotypic contamination in stem cell components collected after 
melphalan and G-CSF mobilization in 15 patients are shown as a function of different 
factors.  In (A), estimates of clonotypic contamination in 20 stem cell components (SCC) are 
shown as a function of the type of PCR assay used. The results with light- and heavy-chain (VL
and VH) patient-specific PCR were correlated (r
2 = 0.93, p << 0.01), and 35% (7/20) of the time 
were equal.  Means were VL = 2.7 and VH = 3.3 x 10
4 clonotypic cells per kg per SCC. 
In (B), estimates of clonotypic contamination in 29 SCC are shown as a function of CD34+ cells 
per kg in each SCC, calculated by flow cytometry.  By simple linear regression, the line of best 
fit is y = (0.707)x – 0.669 with 95% confidence intervals as shown (r
2 = 0.42, F = 19.1, p << 
0.01).  There is a relatively constant ratio of CD34+ and clonotypic cells, as previously suggested 
by Moos and colleagues (18).  In (C), clonotypic contamination is shown in relationship to the 
timing of mobilization.  Medians for days 12-18 and 19-23 were 0.5 and 0.35 x 10
4 clonotypic 
cells per kg.  Differences due to timing of mobilization were not significant (Mann-Wilcoxon, p 
= 0.68). 
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